Tag: M.W=100-150

Moura, Joao published the artcileSARS-CoV-2 infection in patients with neuroimmunological disorders in a tertiary referral centre from the north of Portugal, HPLC of Formula: 624-49-7, the publication is Multiple Sclerosis and Related Disorders (2022), 103893, database is CAplus and MEDLINE.

The impact of COVID-19 in patients with neuroimmunol. disorders is not fully established. There is some evidence suggesting an increased risk of more severe infection associated with the use of immunosuppressors in this population. To characterize SARS-CoV-2 infection in patients followed in the neuroimmunol. outpatient clinic of a tertiary center from the north of Portugal. Retrospective anal. of neuroimmunol. patients with PCR-proven SARS-CoV-2 infection during the observational period of 20 mo. Ninety-one patients were infected, 68.1% female, with a mean age of 48.9±16.7 years. The median disease duration was 11.0 (IQR 6.0-19.0) years. Sixty-one patients (67.0%) had Multiple Sclerosis, of which 50 with relapsing-remitting course, 12 (13.2%) Myasthenia Gravis (MG), 6 (6.6%) Autoimmune Encephalitis and 6 (6.6%) Chronic Inflammatory Demyelinating Polyneuropathy. Seventy-six patients (83.5%) were taking disease-modifying therapy, 77.6% of which were on immunosuppressants, including anti-CD20 in 12 (13.2%). Most patients had mild COVID-19 (84.6%), with 3 cases (3.3%) of severe disease and, 7 cases (7.7%) of critical disease being reported. In total, 13 patients were hospitalized and 4 died. Patients with severe to critical disease were significantly older than patients with milder forms (69.4±21.0 vs. 46.5±14.4 years, p<0.01). MG was also associated with more severe disease (p=0.02). There was no association between comorbidities or use of immunosuppressors (including anti-CD20) and COVID-19 severity. Greater age and MG were associated with severe or critical COVID-19. We found no association between a specific DMT, including anti-CD20, and outcome. Clin. recovery was achieved by 93.4%.

Multiple Sclerosis and Related Disorders published new progress about 624-49-7. 624-49-7 belongs to esters-buliding-blocks, auxiliary class Inhibitor,Natural product, name is Dimethyl fumarate, and the molecular formula is C6H8O4, HPLC of Formula: 624-49-7.

Referemce:
https://en.wikipedia.org/wiki/Ester,
Ester – an overview | ScienceDirect Topics

Albaneze-Walker, Jennifer published the artcilePractical application of new catalytic methods: a concise synthesis of a potent PDE IV inhibitor, Category: esters-buliding-blocks, the publication is Tetrahedron (2005), 61(26), 6330-6336, database is CAplus.

An efficient synthesis of a potent PDE IV inhibitor I is described. The synthesis is highlighted by two practical and efficient catalytic reactions: a highly selective catalytic palladium mediated carbonylation of the pyridine side chain and an efficient palladium-catalyzed Suzuki-Miyaura coupling of a chloropyridine-N-oxide.

Tetrahedron published new progress about 924-99-2. 924-99-2 belongs to esters-buliding-blocks, auxiliary class Alkenyl,Amine,Aliphatic hydrocarbon chain,Ester, name is Ethyl 3-(dimethylamino)acrylate, and the molecular formula is C7H13NO2, Category: esters-buliding-blocks.

Referemce:
https://en.wikipedia.org/wiki/Ester,
Ester – an overview | ScienceDirect Topics

Rauma, Ilkka published the artcileSafety of alemtuzumab in a nationwide cohort of Finnish multiple sclerosis patients, Application of Dimethyl fumarate, the publication is Journal of Neurology (2022), 269(2), 824-835, database is CAplus and MEDLINE.

Alemtuzumab is an effective disease-modifying therapy (DMT) for highly active multiple sclerosis (MS). However, safety concerns limit its use in clin. practice. To evaluate the safety of alemtuzumab in a nationwide cohort of Finnish MS patients. In this retrospective case series study, we analyzed the data of all but two MS patients who had received alemtuzumab in Finland until 2019. Data were systematically collected from patient files. Altogether 121 patients were identified, most of whom had received previous DMTs (82.6%). Median follow-up time after treatment initiation was 30.3 mo and exceeded 24 mo in 78 patients. Infusion-associated reactions (IARs) were observed in 84.3%, 57.3%, and 57.1% of patients during alemtuzumab courses 1-3, resp. Serious adverse events (SAEs) were observed in 32.2% of patients, serious IARs in 12.4% of patients, and SAEs other than IARs in 23.1% of patients. Autoimmune adverse events were observed in 30.6% of patients. One patient died of hemophagocytic lymphohistiocytosis, and one patient died of pneumonia. A previously unreported case of thrombotic thrombocytopenic purpura was documented. SAEs were more frequent in the present cohort than in previous studies. Even though alemtuzumab is a highly effective therapy for MS, vigorous monitoring with a long enough follow-up time is advised.

Journal of Neurology published new progress about 624-49-7. 624-49-7 belongs to esters-buliding-blocks, auxiliary class Inhibitor,Natural product, name is Dimethyl fumarate, and the molecular formula is C6H8O4, Application of Dimethyl fumarate.

Referemce:
https://en.wikipedia.org/wiki/Ester,
Ester – an overview | ScienceDirect Topics

Zhang, Liang published the artcileSulfonium Salts Enable the Direct Sulfenylation of Activated C(sp³)-H Bonds, Synthetic Route of 517-23-7, the publication is European Journal of Organic Chemistry (2021), 2021(9), 1365-1369, database is CAplus.

Herein, the direct α-sulfenylation of a series of β-dicarbonyl, β-ketophosphonate, and β-ketonitrile compounds, mediated by sulfonium salts has been described. Traditionally, sulfonium salts which are synthesized by activation of dialkylsulfoxides serve as oxidizing agents or precursors of sulfur ylide. In this transformation, sulfonium salts as readily prepared and operationally simple sulfenylation reagents firstly achieved alkylsulfenylation of various activated C(sp³)-H bonds with the formation of tetra-substituted carbon center. Thus, e.g., sulfenylation of Me 2-oxocyclopentanecarboxylate with DMSO in presence of AcCl as activator and NaSbF₆ in MeCN afforded I (79%).

European Journal of Organic Chemistry published new progress about 517-23-7. 517-23-7 belongs to esters-buliding-blocks, auxiliary class Tetrahydrofuran,Ketone,Ester, name is 3-Acetyldihydrofuran-2(3H)-one, and the molecular formula is C3H7NO2, Synthetic Route of 517-23-7.

Referemce:
https://en.wikipedia.org/wiki/Ester,
Ester – an overview | ScienceDirect Topics

Lazewska, Dorota published the artcileAlkyl derivatives of 1,3,5-triazine as histamine H₄ receptor ligands, Category: esters-buliding-blocks, the publication is Bioorganic & Medicinal Chemistry (2019), 27(7), 1254-1262, database is CAplus and MEDLINE.

This study focuses on the design, synthesis, mol. modeling and biol. evaluation of a novel group of alkyl-1,3,5-triazinyl-methylpiperazines. New compounds were synthesized and their affinities for human histamine H₄ receptor (hH₄R) were evaluated. Among them, 4-(cyclohexylmethyl)-6-(4-methylpiperazin-1-yl)-1,3,5-triazin-2-amine (14) exhibited hH₄R affinity with a K_i of 160 nM and behaved as antagonist in functional assays: the cellular aequorin-based assay (IC₅₀ = 32 nM) and [³⁵S]GTPγS binding assay (pK_b = 6.67). In addition, antinociceptive activity of 14 in vivo was observed in Formalin test (in mice) and in Carrageenan-induced acute inflammation test (in rats).

Bioorganic & Medicinal Chemistry published new progress about 5340-78-3. 5340-78-3 belongs to esters-buliding-blocks, auxiliary class Aliphatic Chain, name is Ethyltert-butylacetate, and the molecular formula is C8H16O2, Category: esters-buliding-blocks.

Referemce:
https://en.wikipedia.org/wiki/Ester,
Ester – an overview | ScienceDirect Topics

Dembele, Ousmane published the artcileNovel approach towards 3,7-disubstituted 1,6-naphthyridin-4(1H)-ones exploiting cross-coupling and S_NAr reactions of a dihalogenated compound, Application In Synthesis of 924-99-2, the publication is Tetrahedron Letters (2018), 59(39), 3519-3523, database is CAplus.

A new route toward the synthesis of a series of 3,7-disubstituted 1,6-naphthyridin-4(1H)-ones such as I [R¹ = C₆H₄, 3-FC₆H₄, NH(4-MeOC₆H₄), etc.; R² = 4-ClC₆H₄, NHC₆H₅, 4-pyridinyl, etc.] in moderate to good yields was reported. The strategy involved the preparation of 3,7-dihalogenated compound that underwent differential functionalization via palladium-catalyzed Suzuki-Miyaura cross-coupling/Buchwald-Hartwig amination and S_NAr reactions.

Tetrahedron Letters published new progress about 924-99-2. 924-99-2 belongs to esters-buliding-blocks, auxiliary class Alkenyl,Amine,Aliphatic hydrocarbon chain,Ester, name is Ethyl 3-(dimethylamino)acrylate, and the molecular formula is C7H13NO2, Application In Synthesis of 924-99-2.

Referemce:
https://en.wikipedia.org/wiki/Ester,
Ester – an overview | ScienceDirect Topics

Suhrkamp, Ina published the artcileOral Dimethyl Fumarate Targets HCA2-Expressing Skin Cells in the Imiquimod Mouse Model, SDS of cas: 624-49-7, the publication is Journal of Investigative Dermatology (2022), 142(9), 2547-2550.e5, database is CAplus and MEDLINE.

Fumarates (fumaric acid esters, FAEs) are orally administered systemic agents used for the treatment of psoriasis and multiple sclerosis. DMF therapy typically improves skin inflammation within the first 3 mo of treatment. The aim of this study was to evaluate pharmacokinetic parameters of fumaric acid esters (FAE) in psoriasis patients for the first time. Flow cytometry was used to assess T-cell and neutrophil frequencies, apoptosis and activation phenotype. Our results reveal a novel in vivo effect of DMF therapy on pro-inflammatory neutrophils that likely contributes to this treatments antipsoriatic efficacy.

Journal of Investigative Dermatology published new progress about 624-49-7. 624-49-7 belongs to esters-buliding-blocks, auxiliary class Inhibitor,Natural product, name is Dimethyl fumarate, and the molecular formula is C15H14O3, SDS of cas: 624-49-7.

Referemce:
https://en.wikipedia.org/wiki/Ester,
Ester – an overview | ScienceDirect Topics

Sato, Motohide published the artcileNovel HIV-1 Integrase Inhibitors Derived from Quinolone Antibiotics, Category: esters-buliding-blocks, the publication is Journal of Medicinal Chemistry (2006), 49(5), 1506-1508, database is CAplus and MEDLINE.

The viral enzyme integrase is essential for the replication of human immunodeficiency virus type 1 (HIV-1) and represents a remaining target for antiretroviral drugs. Here, we describe the modification of a quinolone antibiotic to produce the novel integrase inhibitor JTK-303 (GS 9137) that blocks strand transfer by the viral enzyme. It shares the core structure of quinolone antibiotics, exhibits an IC₅₀ of 7.2 nM in the strand transfer assay, and shows an EC₅₀ of 0.9 nM in an acute HIV-1 infection assay.

Journal of Medicinal Chemistry published new progress about 924-99-2. 924-99-2 belongs to esters-buliding-blocks, auxiliary class Alkenyl,Amine,Aliphatic hydrocarbon chain,Ester, name is Ethyl 3-(dimethylamino)acrylate, and the molecular formula is C7H13NO2, Category: esters-buliding-blocks.

Referemce:
https://en.wikipedia.org/wiki/Ester,
Ester – an overview | ScienceDirect Topics

Stern, Eric published the artcilePharmacomodulations around the 4-Oxo-1,4-dihydroquinoline-3-carboxamides, a Class of Potent CB₂-Selective Cannabinoid Receptor Ligands: Consequences in Receptor Affinity and Functionality, Recommanded Product: Ethyl 3-(dimethylamino)acrylate, the publication is Journal of Medicinal Chemistry (2007), 50(22), 5471-5484, database is CAplus and MEDLINE.

CB₂ receptor selective ligands are becoming increasingly attractive drugs due to the potential role of this receptor in several physiopathol. processes. Thus, the development of our previously described series of 4-oxo-1,4-dihydroquinoline-3-carboxamides, e.g. I, was pursued with the aim to further characterize the structure-affinity and structure-functionality relationships of these derivatives The influence of the side chain was investigated by synthesizing compounds bearing various carboxamido and keto substituents. On the other hand, the role of the quinoline central scaffold was studied by synthesizing several 6-, 7-, or 8-chloro-4-oxo-1,4-dihydroquinolines, as well as 4-oxo-1,4-dihydronaphthyridine and 4-oxo-1,4-dihydrocinnoline derivatives The effect of these modifications on the affinity and functionality at the CB₂ receptor was studied and allowed for the characterization of new selective CB₂ receptor ligands.

Journal of Medicinal Chemistry published new progress about 924-99-2. 924-99-2 belongs to esters-buliding-blocks, auxiliary class Alkenyl,Amine,Aliphatic hydrocarbon chain,Ester, name is Ethyl 3-(dimethylamino)acrylate, and the molecular formula is C15H24O2, Recommanded Product: Ethyl 3-(dimethylamino)acrylate.

Referemce:
https://en.wikipedia.org/wiki/Ester,
Ester – an overview | ScienceDirect Topics

Dreyer-Alster, Sapir published the artcileCOVID-19 vaccination in patients with multiple sclerosis: Safety and humoral efficacy of the third booster dose, Related Products of esters-buliding-blocks, the publication is Journal of the Neurological Sciences (2022), 120155, database is CAplus and MEDLINE.

As immunity against SARS-COV-2 wanes following first and second doses of vaccination, a third dose is administered in several countries around the world. Similarly to the first doses, risks related to vaccination and humoral immune response in patients with multiple sclerosis (MS) need to be assessed. Characterize safety and humoral immune response following the third dose of COVID-19 vaccination in a large cohort of MS patients. We assessed the safety of the third dose of the BNT162b2-COVID-19 mRNA vaccination in adult MS patients and evaluated SARS-CoV-2 IgG response. Two hundred and eleven adult MS patients received a third dose of BNT162b2 COVID-19 vaccination. Median follow up time was 66 days from vaccine administration (IQR 54-84). The frequency of any adverse event was 54.5%, with the most common reported adverse events being fatigue, local pain at the injection site, fever and muscle or joint pain. Transient increase in MS symptoms was reported in 3.8% of patients, none of them requiring treatment. The rate of acute relapses treated with IV steroids was 3.3%. In a sub-group of 55 patients, 20 untreated and 35 treated with vaccination-safe disease-modifying treatments, SARS-CoV-2 IgG levels increased 21-fold (median ± SD 21.6 ± 53.05). The third dose of COVID-19-BNT162b2 vaccine proved safe for MS patients, with no increased risk of relapse activity. Untreated patients and patients treated with vaccination-safe disease-modifying treatments show significant increase in SARS-CoV-2 IgG levels following the third dose of vaccination.

Journal of the Neurological Sciences published new progress about 624-49-7. 624-49-7 belongs to esters-buliding-blocks, auxiliary class Inhibitor,Natural product, name is Dimethyl fumarate, and the molecular formula is C6H8O4, Related Products of esters-buliding-blocks.

Referemce:
https://en.wikipedia.org/wiki/Ester,
Ester – an overview | ScienceDirect Topics